A Phase 3 interventional study of Amlodipine 5 mg and Placebo in Hypertension, sponsored by Boehringer Ingelheim. Completed at 136 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-27.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 11th largest by enrollment of the 186 interventional ones that give a count, is one of 16 that started in 2006, is one of 69 in phase 3, and was the 19th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 16 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,461 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
122 studies in Hypertension by Boehringer Ingelheim: 1 open now, 1 under way, 1 of them phase 3. Of 120 finished, 41 (34%) have results posted.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 4th largest by enrollment of the 74 interventional ones that give a count, is one of 14 that started in 2006, is one of 43 in phase 3, and was the 24th registered.
Boehringer Ingelheim’s Hypertension studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Boehringer Ingelheim’s 122 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
Inclusion criteria:
Main Inclusion Criteria: Male and female patients >=18 years of age with Stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure >=95 and \<=119 mmHg Main
Exclusion criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo once daily for eight weeks
Drug: Placebo
Telmisartan 20 mg once daily for eight weeks
Drug: Telmisartan 20 mg
Telmisartan 40 mg once daily for eight weeks
Drug: Telmisartan 40 mg
Telmisartan 80 mg once daily for eight weeks
Drug: Telmisartan 80 mg
Amlodipine 2.5 mg once daily for eight weeks
Drug: Amlodipine 2.5 mg
Amlodipine 5 mg once daily for eight weeks
Drug: Amlodipine 5 mg
Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily
Drug: Amlodipine 5 mg · Drug: Amlodipine 10 mg
Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks
Drug: Telmisartan 20 mg · Drug: Amlodipine 2.5 mg
Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks
Drug: Telmisartan 20 mg · Drug: Amlodipine 5 mg
Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Drug: Amlodipine 10 mg · Drug: Telmisartan 20 mg · Drug: Amlodipine 5 mg
Telmisartan 40 / Amlodipine 2.5 for eight weeks
Drug: Amlodipine 2.5 mg · Drug: Telmisartan 40 mg
Telmisartan 40 / Amlodipine 5 for eight weeks
Drug: Amlodipine 5 mg · Drug: Telmisartan 40 mg
Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Drug: Telmisartan 40 mg · Drug: Amlodipine 10 mg · Drug: Amlodipine 5 mg
Telmisartan 80 / Amlodipine 2.5 for eight weeks
Drug: Amlodipine 2.5 mg · Drug: Telmisartan 80 mg
Telmisartan 80 / Amlodipine 5 mg for eight weeks
Drug: Telmisartan 80 mg · Drug: Amlodipine 5 mg
Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Drug: Amlodipine 5 mg · Drug: Telmisartan 80 mg · Drug: Amlodipine 10 mg
Amlodipine 5 mg once daily for two weeks
Placebo to Telmisartan and Amlodipine once daily for eight weeks
Telmisartan 20 mg once daily for eight weeks
Telmisartan 40 mg once daily for eight weeks
Amlodipine 10 mg once daily for six weeks
Telmisartan 20 mg once daily for eight weeks
Telmisartan 80 mg once daily for eight weeks
Amlodipine 10 mg once daily for six weeks
Telmisartan 20 mg once daily for eight weeks
Amlodipine 5 mg once daily for two weeks
amlodipine 5g once daily for eight weeks
Telmisartan 20 mg once daily for eight weeks
Amlodipine 5 mg once daily for eight weeks
amlodipine 5mg once daily for eight weeks
Amlodipine 2.5 mg once daily for eight weeks
Amlodipine 2.5 mg once daily for eight weeks
Amlodipine 10 mg once daily for six weeks
Amlodipine 2.5 mg once daily for eight weeks
Telmisartan 80 mg once daily for eight weeks
Telmisartan 80 mg once daily for eight weeks
Amlodipine 5 mg once daily for two weeks
Amlodipine 2.5 mg once daily for eight weeks
Telmisartan 40 mg once daily for eight weeks
Telmisartan 40 mg once daily for eight weeks
amlodipine 5g once daily for two weeks
Amlodipine 5 mg once daily for eight weeks
Telmisartan 40 mg once daily for eight weeks
Telmisartan 80 mg once daily for eight weeks
Amlodipine 10 mg once daily for six weeks
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Diastolic Blood Pressure (DBP) (Observed Telmisartan Effect)
Observed results
Time frame: Baseline to end-of-study (up to 8 weeks) visit (Last Observation Carried Forward (LOCF))
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Time frame: Baseline to end-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)
Observed results
Time frame: Baseline to end-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Time frame: Baseline to end-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Treatment Effects)
Observed results
Time frame: End-of-study visit (LOCF)
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Time frame: Baseline to end-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Time frame: Baseline to end-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline in Seated Trough Cuff Mean DBP (Observed Telmisartan Effect)
Observed results
Time frame: Baseline to end-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Time frame: Baseline to end-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)
Observed results
Time frame: Up to 8 weeks (LOCF)
Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Time frame: Up to 8 weeks (LOCF)
Change From Baseline in Seated Trough Cuff Mean DBP (Observed Treatment Effects)
Observed results
Time frame: Up to 8 weeks (LOCF)
Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Time frame: Up to 8 weeks (LOCF)
Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Time frame: Up to 8 weeks (LOCF)
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Systolic Blood Pressure (SBP)
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
Time frame: Baseline to end-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline at 8 Weeks in Standing Trough Cuff Mean DBP
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Time frame: Baseline to end-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline at 8 Weeks in Standing Trough Cuff Mean SBP
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
Time frame: Baseline to end-of-study (up to 8 weeks) visit (LOCF)
DBP Control
DBP control is defined as DBP \< 90 mmHg - key combination therapies
Time frame: End-of-study (up to 8 weeks) visit (LOCF)
DBP Response
DBP response is defined as DBP \< 90 mmHg or a reduction of DBP of \>= 10 mmHg - key combination therapies
Time frame: End-of-study (up to 8 weeks) visit (LOCF)
SBP Response
SBP Response is defined as SBP \< 140 mmHg or a reduction of SBP of \>= 10 mmHg - key combination therapies
Time frame: End-of-study (up to 8 weeks) visit (LOCF)
BP Normality
No: Mean seated SBP \>=140 and/or mean seated DBP \>=90 mmHg at trough High normal: mean seated SBP \>=130 and \<140 mmHg and mean seated DBP \>=85 and \<90 mmHg at trough Normal: mean seated SBP \>=120 and \<130 mmHg and mean seated DBP \>=80 and \<85 mmHg at trough Optimal: mean seated SBP \< 120 mmHg and mean seated DBP \<80 mmHg at trough - key combination therapies
Time frame: End-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP
Observed results - key combination therapies
Time frame: End-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline in ABPM Hourly Mean (Relative to Dosing) SBP
Observed results - key combination therapies
Time frame: End-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline in ABPM 24-hour Mean DBP
Observed results - key combination therapies
Time frame: End-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline in ABPM 24-hour Mean SBP
Observed results - key combination therapies
Time frame: End-of-study (up to 8 weeks) visit (LOCF)
Orthostatic Change in Trough Cuff Mean DBP
Calculated as seated minus standing for all patients - key combination therapies
Time frame: Week 8
Orthostatic Change in Trough Cuff Mean SBP
Calculated as seated minus standing for all patients - key combination therapies
Time frame: Week 8
Change From Baseline in Seated Trough Pulse Rate
Observed results for all patients - key combination therapies
Time frame: End-of-study visit (LOCF)
Change From Baseline in Seated Trough Cuff Mean SBP
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
Time frame: Up to 8 weeks (LOCF)
Change From Baseline in Standing Trough Cuff Mean DBP
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Time frame: Up to 8 weeks (LOCF)
Change From Baseline in Standing Trough Cuff Mean SBP
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
Time frame: Up to 8 weeks (LOCF)
DBP Control
DBP control is defined as DBP \< 90 mmHg - key combination therapies
Time frame: Up to 8 weeks (LOCF)
DBP Response
DBP response is defined as DBP \< 90 mmHg or a reduction of DBP of \>= 10 mmHg - key combination therapies
Time frame: Up to 8 weeks (LOCF)
SBP Response
SBP Response is defined as SBP \< 140 mmHg or a reduction of SBP of \>= 10 mmHg - key combination therapies
Time frame: Up to 8 weeks (LOCF)
BP Normality
No: Mean seated SBP \>=140 and/or mean seated DBP \>=90 mmHg at trough High normal: mean seated SBP \>=130 and \<140 mmHg and mean seated DBP \>=85 and \<90 mmHg at trough Normal: mean seated SBP \>=120 and \<130 mmHg and mean seated DBP \>=80 and \<85 mmHg at trough Optimal: mean seated SBP \< 120 mmHg and mean seated DBP \<80 mmHg at trough - key combination therapies
Time frame: Up to 8 weeks (LOCF)
Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP
Observed results for mod-sev patients - key combination therapies
Time frame: Up to 8 weeks (LOCF)
Change From Baseline in ABPM 24-hour Mean DBP
Observed results for mod-sev patients - key combination therapies
Time frame: Up to 8 weeks (LOCF)
Change From Baseline in ABPM 24-hour Mean SBP
Observed results for mod-sev patients - key combination therapies
Time frame: Up to 8 weeks (LOCF)
Orthostatic Change in Trough Cuff Mean DBP
Calculated as seated minus standing for mod-sev patients - key combination therapies
Time frame: Week 8
Orthostatic Change in Trough Cuff Mean SBP
Calculated as seated minus standing for mod-sev patients - key combination therapies
Time frame: Week 8
Change From Baseline in Seated Trough Pulse Rate
Observed results for mod-sev patients - key combination therapies
Time frame: Up to 8 weeks (LOCF)
Clinical Relevant Abnormalities for Laboratory Parameters and Electrocardiogram (ECG)
Clinical relevant abnormalities for laboratory parameters and Electrocardiogram (ECG). New abnormal findings or worsening of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).
Time frame: 8 weeks
Change From Baseline at 2,4,6,and 8 Weeks in Seated Trough Cuff DBP
Observed results for key combination therapies
Time frame: Baseline to nominal week over the trial
BP Control
Percentage of responders (SBP\<140 mmHg and DBP\<90 mmHg) for all patients - key combination therapies
Time frame: End-of-study (up to 8 weeks) visit (LOCF)
Change From Baseline in Seated Trough Cuff DBP
Observed results for mod-sev patients - key combination therapies
Time frame: Nominal week over the trial
BP Control
Responders SBP\<10 mmHg and DBP\<90 mmHg) for mod-sev patients - key combination therapies
Time frame: Up to 8 weeks (LOCF)
| Milestone | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 46 | 42 | 130 | 135 | 44 | 46 | 44 | 47 | 143 | 129 | 48 | 146 | 142 | 50 | 140 | 129 |
| Completed | 39 | 41 | 125 | 118 | 40 | 43 | 39 | 46 | 135 | 117 | 44 | 136 | 129 | 43 | 133 | 116 |
| Not completed | 7 | 1 | 5 | 17 | 4 | 3 | 5 | 1 | 8 | 12 | 4 | 10 | 13 | 7 | 7 | 13 |
| Withdrew: Adverse event | 2 | 0 | 2 | 4 | 1 | 0 | 1 | 0 | 1 | 6 | 0 | 5 | 8 | 2 | 3 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 2 | 0 | 1 | 1 | 3 |
| Withdrew: Withdrawal by subject | 3 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 4 | 1 | 1 | 2 | 2 | 1 | 5 |
| Withdrew: Lack of efficacy | 2 | 1 | 1 | 6 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 1 | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Randomised in error; pregnancy; moving | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 2 | 0 | 1 | 2 |
Observed results
| mmHg | Telmisartan 0 mg (T0) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) |
|---|---|---|---|---|
| Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Diastolic Blood Pressure (DBP) (Observed Telmisartan Effect) | -13 ± 8.8 | -16.4 ± 7.8 | -16.2 ± 8.9 | -16.9 ± 8.6 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
| mmHg | Telmisartan 0 mg (T0) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) |
|---|---|---|---|---|
| Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects) | -12.5 ± 0.5 | -16.8 ± 0.6 | -16.6 ± 0.4 | -17.2 ± 0.4 |
Observed results
| mmHg | Placebo (Pl) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|
| Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects) | -12.3 ± 9.7 | -14.9 ± 8.8 | -15.6 ± 8.1 | -18.6 ± 7.7 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
| mmHg | Placebo (Pl) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|
| Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects) | -12.2 ± 0.5 | -15.3 ± 0.6 | -16.2 ± 0.4 | -19.3 ± 0.4 |
Observed results
| mmHg | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Treatment Effects) | -5.9 ± 9.4 | -13.2 ± 9 | -13.1 ± 10.1 | -13.6 ± 8.7 | -18 ± 7.8 | -15.7 ± 6.5 | -18.7 ± 7 | -16.2 ± 8.2 | -16 ± 7.6 | -19.6 ± 7.9 | -15.3 ± 7.5 | -17.8 ± 8.5 | -19.6 ± 7.9 | -10.4 ± 9.9 | -13 ± 7.9 | -16.5 ± 7.1 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
| mmHg | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects) | -6.2 ± 1.2 | -13.8 ± 1.3 | -13.4 ± 0.7 | -14 ± 0.7 | -18.3 ± 1.2 | -15.9 ± 1.2 | -19.3 ± 1.3 | -16.9 ± 1.2 | -16.5 ± 0.7 | -20.2 ± 0.7 | -15.7 ± 1.2 | -18.2 ± 0.7 | -20.1 ± 0.7 | -10.6 ± 1.2 | -13.4 ± 0.7 | -17.11 ± 0.7 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
| mmHg | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl) | -13.8 ± 1.2 | -13.4 ± 0.7 | -14 ± 0.7 | -18.3 ± 1.2 | -15.9 ± 1.2 | -19.3 ± 1.3 | -16.9 ± 1.2 | -16.5 ± 0.7 | -20.2 ± 0.7 | -15.7 ± 1.2 | -18.2 ± 0.7 | -20.1 ± 0.7 | -10.6 ± 1.2 | -13.4 ± 0.7 | -17.1 ± 0.7 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
| mmHg | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Systolic Blood Pressure (SBP) | -2.5 ± 1.8 | -15.1 ± 1.9 | -14.6 ± 1.1 | -14.3 ± 1.1 | -18.8 ± 1.9 | -21 ± 1.9 | -24.4 ± 2 | -21.9 ± 1.8 | -21.8 ± 1.1 | -24.7 ± 1.1 | -17.4 ± 1.8 | -22.1 ± 1 | -26.4 ± 1.1 | -11.4 ± 1.8 | -15.4 ± 1.1 | -20.7 ± 1.1 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
| mmHg | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline at 8 Weeks in Standing Trough Cuff Mean DBP | -4.9 ± 1.2 | -10.4 ± 1.3 | -10 ± 0.8 | -11.1 ± 0.8 | -14.9 ± 1.3 | -13.1 ± 1.3 | -16.9 ± 1.3 | -15.8 ± 1.2 | -13.6 ± 0.7 | -18.4 ± 0.8 | -13.4 ± 1.2 | -16.2 ± 0.7 | -19 ± 0.7 | -8.1 ± 1.2 | -11.3 ± 0.7 | -14.6 ± 0.8 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
| mmHg | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline at 8 Weeks in Standing Trough Cuff Mean SBP | -0.5 ± 1.9 | -13.2 ± 2 | -13.2 ± 1.1 | -12.9 ± 1.1 | -17.4 ± 1.9 | -18.9 ± 1.9 | -22.3 ± 2 | -20.3 ± 1.8 | -20 ± 1.1 | -22.8 ± 1.1 | -17.4 ± 1.9 | -21.2 ± 1.1 | -24.9 ± 1.1 | -9.1 ± 1.9 | -14.7 ± 1.1 | -19.1 ± 1.2 |
Observed results for key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Week 2 | -14.5 ± 8.76 | -14.4 ± 7.62 | -15.3 ± 7.87 | -14.6 ± 6.76 |
| Week 4 (N=133, 115, 135, 129) | -16.0 ± 7.24 | -18.1 ± 8.52 | -17.2 ± 7.56 | -18.8 ± 7.06 |
| Week 6 (N=134, 118, 131, 124) | -17.1 ± 8.59 | -19.0 ± 8.30 | -18.0 ± 8.02 | -20.0 ± 8.18 |
| Week 8 (N=133, 112, 132, 121) | -16.3 ± 7.42 | -19.5 ± 8.03 | -18.3 ± 8.28 | -20.0 ± 7.61 |
DBP control is defined as DBP \< 90 mmHg - key combination therapies
| percentage of participants | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| DBP Control | 71.6 | 82.1 | 74.8 | 85.3 |
DBP response is defined as DBP \< 90 mmHg or a reduction of DBP of \>= 10 mmHg - key combination therapies
| percentage of participants | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| DBP Response | 80.9 | 91.9 | 88.8 | 91.2 |
SBP Response is defined as SBP \< 140 mmHg or a reduction of SBP of \>= 10 mmHg - key combination therapies
| percentage of participants | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| SBP Response | 91.5 | 96.7 | 87.4 | 94.9 |
Percentage of responders (SBP\<140 mmHg and DBP\<90 mmHg) for all patients - key combination therapies
| percentage of participants | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| BP Control | 58.9 | 75.6 | 65.7 | 76.5 |
No: Mean seated SBP \>=140 and/or mean seated DBP \>=90 mmHg at trough High normal: mean seated SBP \>=130 and \<140 mmHg and mean seated DBP \>=85 and \<90 mmHg at trough Normal: mean seated SBP \>=120 and \<130 mmHg and mean seated DBP \>=80 and \<85 mmHg at trough Optimal: mean seated SBP \< 120 mmHg and mean seated DBP \<80 mmHg at trough - key combination therapies
| percentage of participants | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| No (SBP>=140 and/or DBP>=90) | 41.1 | 24.4 | 34.3 | 23.5 |
| High Normal (140>SBP>=130 and 90>DBP>=85) | 28.4 | 30.1 | 30.1 | 22.1 |
| Normal (130>SBP>=120 and 85>DBP>=80) | 21.3 | 32.5 | 25.9 | 39.7 |
| Optimal (SBP<120 and DBP<80) | 9.2 | 13 | 9.8 | 14.7 |
Observed results - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Hour 1 | -10.7 ± 9.5 | -15.4 ± 11.6 | -12.7 ± 9.9 | -13.4 ± 9.7 |
| Hour 2 | -9.8 ± 11.7 | -15 ± 12.2 | -13.4 ± 9.5 | -14.6 ± 12.4 |
| Hour 3 | -11.2 ± 13.2 | -14.1 ± 12.6 | -14.8 ± 11.6 | -15.4 ± 12 |
| Hour 4 | -11.3 ± 11.8 | -16.5 ± 13.2 | -15.6 ± 11.7 | -15.8 ± 10.8 |
| Hour 5 | -13.1 ± 11 | -14.1 ± 14.4 | -16.3 ± 14.3 | -15.7 ± 10.9 |
| Hour 6 | -10.9 ± 11.6 | -14.5 ± 12.4 | -14.6 ± 9.9 | -16.4 ± 11 |
| Hour 7 | -12.8 ± 10.2 | -15.6 ± 13.9 | -12.9 ± 10.4 | -15.7 ± 14 |
| Hour 8 | -12.1 ± 12.3 | -17.4 ± 13.6 | -12.7 ± 13.6 | -17.1 ± 12.9 |
| Hour 9 | -13.1 ± 10.3 | -15.7 ± 14.4 | -14.3 ± 14.3 | -17.2 ± 13.8 |
| Hour 10 | -11.8 ± 10.3 | -13.8 ± 13.5 | -14.7 ± 15.7 | -18.5 ± 12.9 |
| Hour 11 | -11.2 ± 12.9 | -14.4 ± 11.9 | -15.1 ± 13.1 | -16.1 ± 12.8 |
| Hour 12 | -12 ± 11.3 | -13.3 ± 12.9 | -12.5 ± 14.8 | -15.7 ± 12.2 |
| Hour 13 | -10.3 ± 11.7 | -14.7 ± 14.3 | -14.1 ± 13.5 | -15.1 ± 10.6 |
| Hour 14 | -8.9 ± 13.2 | -14.8 ± 14.1 | -13.4 ± 13.4 | -11 ± 14.9 |
| Hour 15 | -10.3 ± 16 | -11.5 ± 14.3 | -11.9 ± 14.8 | -10 ± 12.7 |
| Hour 16 | -10.1 ± 15 | -10.3 ± 15.4 | -11.3 ± 12 | -12.2 ± 13.6 |
| Hour 17 | -9.8 ± 13.7 | -10.4 ± 14.4 | -11.2 ± 12.5 | -11.5 ± 13.1 |
| Hour 18 | -11.9 ± 15 | -9.9 ± 12.4 | -10.3 ± 12.3 | -12.2 ± 11.9 |
| Hour 19 | -9.1 ± 10.9 | -10.5 ± 13.7 | -11.9 ± 10.4 | -13.2 ± 11.3 |
| Hour 20 | -11 ± 11.9 | -9.9 ± 12.4 | -12.6 ± 11.1 | -15.9 ± 11.1 |
| Hour 21 | -10.4 ± 13 | -8.9 ± 13.2 | -8.5 ± 12.7 | -14.8 ± 9.7 |
| Hour 22 | -11.1 ± 12.6 | -9.8 ± 13.7 | -9.7 ± 12.9 | -15.4 ± 9.9 |
| Hour 23 | -9.8 ± 11.3 | -13.3 ± 13.4 | -9.9 ± 12.2 | -14.6 ± 9.4 |
| Hour 24 | -11.1 ± 9.5 | -12.6 ± 11.5 | -12 ± 13.1 | -13.1 ± 11.9 |
Observed results - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Hour 1 | -18.7 ± 12.9 | -20.2 ± 16.5 | -19.1 ± 13.4 | -17.5 ± 15.9 |
| Hour 2 | -13.1 ± 16.5 | -22.0 ± 17.9 | -20.5 ± 16.6 | -21.9 ± 15.9 |
| Hour 3 | -15.3 ± 16.1 | -17.9 ± 18.9 | -21.1 ± 17.8 | -22.4 ± 16.8 |
| Hour 4 | -18.0 ± 16.9 | -24.4 ± 20.6 | -22.5 ± 16.5 | -23.8 ± 15.9 |
| Hour 5 | -19.3 ± 13.6 | -21.1 ± 19.8 | -25.3 ± 18.1 | -24.0 ± 16.5 |
| Hour 6 | -14.1 ± 14.0 | -22.6 ± 14.9 | -21.6 ± 15.9 | -24.6 ± 14.8 |
| Hour 7 | -17.8 ± 14.5 | -24.3 ± 19.5 | -19.9 ± 17.7 | -22.4 ± 15.6 |
| Hour 8 | -18.8 ± 17.1 | -24.1 ± 20.8 | -20.3 ± 18.6 | -21.8 ± 15.5 |
| Hour 9 | -20.3 ± 15.6 | -24.9 ± 20.0 | -22.0 ± 19.2 | -25.6 ± 16.1 |
| Hour 10 | -20.0 ± 16.0 | -22.9 ± 19.2 | -22.5 ± 19.3 | -26.8 ± 19.3 |
| Hour 11 | -18.7 ± 17.4 | -20.9 ± 19.8 | -23.2 ± 16.7 | -24.9 ± 15.7 |
| Hour 12 | -18.4 ± 16.8 | -20.3 ± 19.5 | -19.7 ± 19.1 | -25.0 ± 17.3 |
| Hour 13 | -18.5 ± 16.9 | -21.7 ± 23.5 | -22.7 ± 18.3 | -24.7 ± 14.6 |
| Hour 14 | -16.7 ± 17.6 | -21.6 ± 20.8 | -21.7 ± 19.2 | -20.2 ± 16.9 |
| Hour 15 | -15.7 ± 18.1 | -19.4 ± 20.5 | -19.0 ± 20.2 | -18.9 ± 15.1 |
| Hour 16 | -17.0 ± 16.9 | -17.7 ± 20.0 | -18.0 ± 16.0 | -19.8 ± 15.4 |
| Hour 17 | -17.3 ± 17.3 | -17.9 ± 20.3 | -14.7 ± 15.8 | -19.1 ± 15.5 |
| Hour 18 | -17.5 ± 18.6 | -17.4 ± 16.4 | -15.1 ± 16.8 | -19.6 ± 16.6 |
| Hour 19 | -16.5 ± 15.6 | -19.7 ± 18.4 | -16.9 ± 15.3 | -20.9 ± 17.3 |
| Hour 20 | -17.8 ± 16.4 | -18.0 ± 17.4 | -16.5 ± 15.3 | -24.4 ± 14.3 |
| Hour 21 | -17.5 ± 15.9 | -17.8 ± 17.6 | -15.7 ± 16.4 | -22.7 ± 15.0 |
| Hour 22 | -16.2 ± 15.9 | -15.7 ± 17.0 | -15.5 ± 18.7 | -23.8 ± 13.8 |
| Hour 23 | -14.4 ± 14.6 | -18.9 ± 16.1 | -16.5 ± 19.1 | -22.4 ± 14.0 |
| Hour 24 | -15.8 ± 14.9 | -20.7 ± 16.3 | -18.5 ± 18.1 | -19.9 ± 13.9 |
Observed results - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Change From Baseline in ABPM 24-hour Mean DBP | -11 ± 7.2 | -13.2 ± 7.7 | -12.8 ± 7.4 | -14.6 ± 6.9 |
Observed results - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Change From Baseline in ABPM 24-hour Mean SBP | -17.3 ± 10.4 | -20.5 ± 13.9 | -19.5 ± 11.6 | -22.4 ± 9.8 |
Calculated as seated minus standing for all patients - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Orthostatic Change in Trough Cuff Mean DBP | 2.2 ± 5.7 | 1.7 ± 5.4 | 2 ± 5.4 | 1.1 ± 4.9 |
Calculated as seated minus standing for all patients - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Orthostatic Change in Trough Cuff Mean SBP | 0 ± 7.5 | 0.6 ± 8 | 0.9 ± 7.5 | 0.8 ± 7.3 |
Observed results
| mmHg | Telmisartan 0 mg (T0) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) |
|---|---|---|---|---|
| Change From Baseline in Seated Trough Cuff Mean DBP (Observed Telmisartan Effect) | -13.1 ± 9 | -16.8 ± 8 | -16.9 ± 8.9 | -17.7 ± 8.8 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
| mmHg | Placebo (Pl) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|
| Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects) | -12.7 ± 0.5 | -17.3 ± 0.7 | -17.3 ± 0.5 | -18 ± 0.5 |
Observed results
| mmHg | Amlodipine 0 mg (A0) - Overall | Amlodipine 2.5 mg (A2.5) - Overall | Amlodipine 5 mg (A5) - Overall | Amlodipine 10 mg (A10) - Overall |
|---|---|---|---|---|
| Change From Baseline in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects) | -12.7 ± 10.1 | -16 ± 8.4 | -16.3 ± 8.3 | -19.2 ± 7.8 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
| mmHg | Amlodipine 0 mg (A0) - Overall | Amlodipine 2.5 mg (A2.5) - Overall | Amlodipine 5 mg (A5) - Overall | Amlodipine 10 mg (A10) - Overall |
|---|---|---|---|---|
| Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects) | -12.5 ± 0.5 | -16.4 ± 0.7 | -16.7 ± 0.5 | -19.7 ± 0.5 |
Observed results
| mmHg | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Seated Trough Cuff Mean DBP (Observed Treatment Effects) | -5.5 ± 10.1 | -13.9 ± 9.4 | -13.8 ± 10.2 | -13.9 ± 9.2 | -18.4 ± 7.9 | -15.8 ± 6.4 | -19.5 ± 7.2 | -18.7 ± 7.9 | -16.8 ± 7.5 | -19.6 ± 8.3 | -16.3 ± 7.7 | -18.8 ± 9 | -20.4 ± 7.3 | -11.4 ± 8.3 | -13.1 ± 8.1 | -17.1 ± 7.6 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
| mmHg | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects) | -5.8 ± 1.4 | -14.4 ± 1.4 | -14.2 ± 0.8 | -14.1 ± 0.9 | -18.9 ± 1.4 | -15.9 ± 1.4 | -19.7 ± 1.6 | -18.8 ± 1.5 | -17.2 ± 0.8 | -20.1 ± 0.8 | -16.6 ± 1.4 | -19.1 ± 0.8 | -21 ± 0.8 | -11.7 ± 1.4 | -13.3 ± 0.8 | -17.6 ± 0.9 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
| mmHg | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl) | -14.5 ± 1.4 | -14.2 ± 0.8 | -14.1 ± 0.9 | -18.9 ± 1.4 | -15.9 ± 1.4 | -19.7 ± 1.5 | -18.8 ± 1.5 | -17.2 ± 0.8 | -20.1 ± 0.8 | -16.6 ± 1.4 | -19.1 ± 0.8 | -21 ± 0.8 | -11.7 ± 1.3 | -13.3 ± 0.8 | -17.6 ± 0.9 |
Observed results for all patients - key combination therapies
| bpm | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Change From Baseline in Seated Trough Pulse Rate | 0 ± 8.8 | 0 ± 9.5 | 2.4 ± 9.3 | -1.5 ± 9.7 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
| mmHg | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Seated Trough Cuff Mean SBP | -1.9 ± 2.1 | -15.6 ± 2.1 | -15.4 ± 1.2 | -15.4 ± 1.3 | -19 ± 2.1 | -22.1 ± 2.1 | -25.2 ± 2.3 | -23.2 ± 2.2 | -22.2 ± 1.2 | -25.3 ± 1.3 | -17.4 ± 2 | -22.5 ± 1.2 | -26.5 ± 1.2 | -12.4 ± 2 | -14.8 ± 1.2 | -21 ± 1.4 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
| mmHg | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Standing Trough Cuff Mean DBP | -4.2 ± 1.4 | -11.7 ± 1.5 | -10.9 ± 0.9 | -11.3 ± 0.9 | -15.1 ± 1.4 | -13.3 ± 1.4 | -17.6 ± 1.6 | -17.5 ± 1.5 | -14.2 ± 0.8 | -18 ± 0.9 | -14.5 ± 1.4 | -17.3 ± 0.8 | -19.2 ± 0.8 | -8 ± 1.4 | -11 ± 0.8 | -15.5 ± 0.9 |
Observed results for mod-sev patients - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Week 2 | -14.7 ± 8.9 | -14.7 ± 7.8 | -16.1 ± 7.9 | -14.9 ± 6.7 |
| Week 4 (N=102, 90, 102, 96) | -16.5 ± 6.8 | -18.2 ± 9.2 | -17.8 ± 7.6 | -19.2 ± 6.8 |
| Week 6 (N=102, 92, 98, 96) | -17.9 ± 7.8 | -19.7 ± 8.7 | -18.9 ± 8.2 | -19.5 ± 8.4 |
| Week 8 (N=102, 87, 99, 88) | -17.1 ± 7.4 | -19.4 ± 8.5 | -19.3 ± 8.7 | -21.1 ± 7.1 |
Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
| mmHg | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Standing Trough Cuff Mean SBP | 1 ± 2.1 | -13.7 ± 2.1 | -13.6 ± 1.2 | -14 ± 1.3 | -16.2 ± 2.1 | -19.4 ± 2.1 | -23.2 ± 2.3 | -21.8 ± 2.2 | -20.4 ± 1.2 | -22.8 ± 1.3 | -16.3 ± 2 | -21.9 ± 1.2 | -24.3 ± 1.2 | -10.1 ± 2.1 | -13.2 ± 1.2 | -19.3 ± 1.4 |
DBP control is defined as DBP \< 90 mmHg - key combination therapies
| percentage of participants | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| DBP Control | 69.4 | 77.1 | 68.9 | 85 |
DBP response is defined as DBP \< 90 mmHg or a reduction of DBP of \>= 10 mmHg - key combination therapies
| percentage of participants | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| DBP Response | 81.5 | 89.6 | 87.7 | 93 |
Responders SBP\<10 mmHg and DBP\<90 mmHg) for mod-sev patients - key combination therapies
| percentage of participants | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| BP Control | 53.7 | 70.8 | 58.5 | 77 |
SBP Response is defined as SBP \< 140 mmHg or a reduction of SBP of \>= 10 mmHg - key combination therapies
| percentage of participants | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| SBP Response | 88.9 | 96.9 | 84.9 | 95 |
No: Mean seated SBP \>=140 and/or mean seated DBP \>=90 mmHg at trough High normal: mean seated SBP \>=130 and \<140 mmHg and mean seated DBP \>=85 and \<90 mmHg at trough Normal: mean seated SBP \>=120 and \<130 mmHg and mean seated DBP \>=80 and \<85 mmHg at trough Optimal: mean seated SBP \< 120 mmHg and mean seated DBP \<80 mmHg at trough - key combination therapies
| percentage of participants | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| No (SBP>=140 and/or DBP>=90) | 46.3 | 29.2 | 41.5 | 23 |
| High Normal (140>SBP>=130 and 90>DBP>=85) | 25.9 | 29.2 | 26.4 | 27 |
| Normal (130>SBP>=120 and 85>DBP>=80) | 18.5 | 30.2 | 21.7 | 41 |
| Optimal (SBP<120 and DBP<80) | 9.3 | 11.5 | 10.4 | 9 |
Observed results for mod-sev patients - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Hour 1 | -11 ± 10.8 | -16.9 ± 10.8 | -13.8 ± 10.1 | -13.7 ± 10.3 |
| Hour 2 | -8.8 ± 12.3 | -16.3 ± 12.5 | -13.9 ± 9.3 | -15.9 ± 13 |
| Hour 3 | -11.2 ± 14.4 | -13.8 ± 11.2 | -16.4 ± 11.3 | -16.1 ± 11.7 |
| Hour 4 | -10.7 ± 12.4 | -16.3 ± 13.6 | -15.9 ± 11.8 | -16.8 ± 11.3 |
| Hour 5 | -12.8 ± 10.5 | -15.3 ± 14.3 | -17.2 ± 14.3 | -16.6 ± 10.9 |
| Hour 6 | -10.5 ± 12.2 | -15.3 ± 12.6 | -15.2 ± 10.1 | -16.3 ± 11.8 |
| Hour 7 | -13.8 ± 11.1 | -15.3 ± 11.4 | -12.9 ± 10.9 | -17.5 ± 14.6 |
| Hour 8 | -13.3 ± 13.1 | -19.4 ± 13.7 | -13.5 ± 14.2 | -17.8 ± 13.7 |
| Hour 9 | -14 ± 11 | -16.6 ± 14.2 | -15.8 ± 14.3 | -18.1 ± 14.1 |
| Hour 10 | -10.7 ± 11.1 | -14.6 ± 14 | -17 ± 14.2 | -20.8 ± 13.2 |
| Hour 11 | -11.4 ± 13.9 | -14.8 ± 12.6 | -16.8 ± 10.5 | -17.9 ± 12.9 |
| Hour 12 | -12.4 ± 12.2 | -13.9 ± 12.4 | -14.3 ± 12.2 | -16.6 ± 12.9 |
| Hour 13 | -9.7 ± 13 | -14.9 ± 14.5 | -14.1 ± 12.5 | -15.9 ± 10.9 |
| Hour 14 | -8.5 ± 14.3 | -14.5 ± 14.6 | -15.1 ± 11.2 | -12 ± 14.6 |
| Hour 15 | -10.5 ± 16.6 | -10.5 ± 13.6 | -13.8 ± 14.7 | -10 ± 12.9 |
| Hour 16 | -10.9 ± 15 | -10.3 ± 16.3 | -12.8 ± 12.2 | -13.7 ± 13 |
| Hour 17 | -10.1 ± 14.1 | -9.8 ± 14.9 | -11.5 ± 12.5 | -12.3 ± 10.8 |
| Hour 18 | -11.8 ± 15.6 | -9.9 ± 13.5 | -10.6 ± 10.3 | -12.8 ± 10.8 |
| Hour 19 | -9 ± 11.7 | -11.6 ± 13.9 | -12.2 ± 10.6 | -12.5 ± 11.8 |
| Hour 20 | -10 ± 12.3 | -10.9 ± 13.1 | -13.3 ± 11.2 | -15.7 ± 11.5 |
| Hour 21 | -10.5 ± 12.3 | -8.6 ± 14.3 | -8.4 ± 12.1 | -15.1 ± 9.4 |
| Hour 22 | -10.9 ± 11.3 | -10 ± 14.6 | -10.2 ± 13.5 | -15.2 ± 10.2 |
| Hour 23 | -10 ± 11.8 | -14 ± 13.8 | -10 ± 12.5 | -14.3 ± 8.5 |
| Hour 24 | -9.7 ± 9.8 | -13.6 ± 11.2 | -13.2 ± 13.8 | -14.4 ± 12.2 |
Observed results for mod-sev patients - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Change From Baseline in ABPM 24-hour Mean DBP | -11 ± 7.7 | -13.6 ± 8 | -13.6 ± 7.1 | -15.3 ± 7 |
Observed results for mod-sev patients - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Change From Baseline in ABPM 24-hour Mean SBP | -16.7 ± 11.3 | -20.8 ± 14.1 | -20.9 ± 11 | -22.7 ± 9.9 |
Calculated as seated minus standing for mod-sev patients - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Orthostatic Change in Trough Cuff Mean DBP | 2.5 ± 5.1 | 2 ± 5.7 | 1.4 ± 5.3 | 1.6 ± 4.5 |
Calculated as seated minus standing for mod-sev patients - key combination therapies
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Orthostatic Change in Trough Cuff Mean SBP | 0 ± 7.1 | 1.4 ± 8.1 | 0.1 ± 6.9 | 1.1 ± 6.3 |
Observed results for mod-sev patients - key combination therapies
| bpm | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) |
|---|---|---|---|---|
| Change From Baseline in Seated Trough Pulse Rate | 0.5 ± 8.8 | 0 ± 9 | 2.5 ± 9.2 | -1.9 ± 8.9 |
Clinical relevant abnormalities for laboratory parameters and Electrocardiogram (ECG). New abnormal findings or worsening of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).
| percentage of participants | Placebo (Pl) | Telmisartan Monotherapy | Amlodipine Monotherapy | Combination Therapy |
|---|---|---|---|---|
| Alanine aminotransferase increased | 0.0 | 0.3 | 0.0 | 0.1 |
| Aspartate aminotransferase increased | 0.0 | 0.3 | 0.0 | 0.1 |
| Blood potassium increased | 0.0 | 0.3 | 0.0 | 0.0 |
| Electrocardiogram QT shortened | 0.0 | 0.0 | 0.3 | 0.0 |
| Electrocardiogram T wave abnormal | 0.0 | 0.0 | 0.3 | 0.1 |
| Electrocardiogram repolarisation abnormality | 0.0 | 0.0 | 0.0 | 0.1 |
| Heart rate irregular | 0.0 | 0.0 | 0.3 | 0.0 |
| QRS axis abnormal | 0.0 | 0.0 | 0.3 | 0.0 |
| Atrioventricular block first degree | 0.0 | 0.0 | 0.0 | 0.3 |
| Left atrial dilatation | 0.0 | 0.0 | 0.0 | 0.1 |
| Myocardial ischaemia | 0.0 | 0.1 | 0.0 | 0.0 |
| Palpitation | 0.0 | 0.0 | 0.6 | 0.1 |
| Sinus bradycardia | 0.0 | 0.0 | 0.0 | 0.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PLACEBO | — | 0/46 (0%) | — |
| Telmisartan 20 mg (T20) | — | 0/42 (0%) | — |
| Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | — | 0/44 (0%) | — |
| Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | — | 0/46 (0%) | — |
| Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | — | 0/44 (0%) | — |
| Telmisartan 40 mg (T40) | — | 0/130 (0%) | — |
| Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | — | 0/47 (0%) | — |
| Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | — | 0/143 (0%) | — |
| Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | — | 0/129 (0%) | — |
| Telmisartan 80 mg (T80) | — | 1/135 (0.7%) | — |
| Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | — | 2/48 (4.2%) | — |
| Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | — | 2/146 (1.4%) | — |
| Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | — | 0/142 (0%) | — |
| Amlodipine 2.5 mg (A2.5) | — | 1/50 (2%) | — |
| Amlodipine 5 mg (A5) | — | 1/140 (0.7%) | — |
| Amlodipine 10 mg (A10) | — | 0/129 (0%) | — |
| Event | PLACEBO | Telmisartan 20 mg (T20) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg (T40) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg (T80) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chest painGeneral disorders | 0/46 | 0/42 | 0/44 | 0/46 | 0/44 | 0/130 | 0/47 | 0/143 | 0/129 | 0/135 | 1/48 | 1/146 | 0/142 | 0/50 | 0/140 | 0/129 |
| SinusitisInfections and infestations | 0/46 | 0/42 | 0/44 | 0/46 | 0/44 | 0/130 | 0/47 | 0/143 | 0/129 | 0/135 | 1/48 | 0/146 | 0/142 | 0/50 | 0/140 | 0/129 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/46 | 0/42 | 0/44 | 0/46 | 0/44 | 0/130 | 0/47 | 0/143 | 0/129 | 0/135 | 0/48 | 0/146 | 0/142 | 1/50 | 0/140 | 0/129 |
| ChokingRespiratory, thoracic and mediastinal disorders | 0/46 | 0/42 | 0/44 | 0/46 | 0/44 | 0/130 | 0/47 | 0/143 | 0/129 | 1/135 | 0/48 | 0/146 | 0/142 | 0/50 | 0/140 | 0/129 |
| DiverticulitisInfections and infestations | 0/46 | 0/42 | 0/44 | 0/46 | 0/44 | 0/130 | 0/47 | 0/143 | 0/129 | 0/135 | 0/48 | 0/146 | 0/142 | 0/50 | 1/140 | 0/129 |
| Deep vein thrombosisVascular disorders | 0/46 | 0/42 | 0/44 | 0/46 | 0/44 | 0/130 | 0/47 | 0/143 | 0/129 | 0/135 | 0/48 | 1/146 | 0/142 | 0/50 | 0/140 | 0/129 |
| Event | PLACEBO | Telmisartan 20 mg (T20) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg (T40) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg (T80) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 0/46 | 0/42 | 1/44 | 2/46 | 5/44 | 1/130 | 0/47 | 2/143 | 7/129 | 1/135 | 1/48 | 3/146 | 16/142 | 1/50 | 1/140 | 23/129 |
| HeadacheNervous system disorders | 5/46 | 3/42 | 3/44 | 4/46 | 2/44 | 11/130 | 3/47 | 7/143 | 5/129 | 4/135 | 0/48 | 6/146 | 7/142 | 2/50 | 9/140 | 7/129 |
| Chest painGeneral disorders | 1/46 | 3/42 | 0/44 | 0/46 | 0/44 | 2/130 | 0/47 | 1/143 | 1/129 | 0/135 | 0/48 | 1/146 | 0/142 | 0/50 | 0/140 | 1/129 |
Treated set including all 1461 patients who were randomised to receive double-blind treatment and took at least one dose.
| Age, Continuous(Years) | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 52.5 ± 12.3 | 53.6 ± 10.4 | 52 ± 11 | 53.1 ± 11.3 | 54 ± 10.8 | 54.4 ± 10.2 | 51 ± 11.2 | 50.7 ± 10.2 | 52.3 ± 11.9 | 53.3 ± 11.3 | 54.8 ± 9.7 | 52.7 ± 11.9 | 53.9 ± 11.6 | 55.3 ± 10.4 | 53.1 ± 10.6 | 53.4 ± 10.7 | 53.1 ± 11.1 |
| Sex: Female, Male(Participants) | Placebo (Pl) | Telmisartan 20 mg (T20) | Telmisartan 40 mg (T40) | Telmisartan 80 mg (T80) | Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5) | Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5) | Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10) | Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5) | Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5) | Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10) | Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5) | Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5) | Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10) | Amlodipine 2.5 mg (A2.5) | Amlodipine 5 mg (A5) | Amlodipine 10 mg (A10) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 17 | 16 | 64 | 75 | 18 | 25 | 18 | 21 | 72 | 67 | 26 | 72 | 78 | 23 | 68 | 64 | 724 |
| Male | 29 | 26 | 66 | 60 | 26 | 21 | 26 | 26 | 71 | 62 | 22 | 74 | 64 | 27 | 72 | 65 | 737 |
Showing the first 100 of 136 sites across 5 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2006 and a primary completion of Mar 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amlodipine · Telmisartan